๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 7 Beijing 6 Hangzhou 5 Fuzhou 3 Harbin 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou7 Beijing6 Hangzhou5 Fuzhou3 Harbin3
All 28 locations
Target enrolment
to

Trials with a site in Hangzhou

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7ร—19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
NCT07788118Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transforming Follicular Lymphoma (tFL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
70
Hangzhou
2026-09-01
Not yet open
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07669194Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
30
Hangzhou
2026-06-10
Recruiting
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
NCT07078500Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2025-05-05
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT06464861Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
52
Hangzhou
2024-06-20
Recruiting
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

4 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 5 studies
PhaseStudiesRecruitingShare
Phase 22240%
Observational1020%
Phase 11120%
Phase 1/21120%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine43
Xynomic Pharmaceuticals, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.